Amgen’s PRMT5 drug shows 5 partial responses from 31 patients, STATnews reports

Amgen (AMGN) on Friday presented preliminary results from its first study on a cancer drug target called PRMT5 that selectively blocks the enzyme in cancer cells, showing five partial responses from 31 evaluable patients, STATnews’ Adam Feuerstein reports. Previously, a rival PRMT5 inhibitor being developed by Mirati Therapeutics (MRTX) factored into Bristol Myers Squibb’s (BMY) decision to acquire the company.